- Zylidac Bio and Prolific Machines have partnered to scale Prolific’s optogenetics-enabled biologics manufacturing platform from early development to GMP production.
- The collaboration will begin with technology transfer at 50-liter scale, with plans to advance programs to 250 liters and subsequently to GMP manufacturing.

Zylidac Bio LLC, a biologics contract development and manufacturing organization (CDMO) within the Zydus Lifesciences group, has partnered with biotechnology company Prolific Machines to scale Prolific’s optogenetics-enabled platform from early development through good manufacturing practice (GMP) production. Both companies are headquartered in Emeryville, California, in the San Francisco Bay Area.
The collaboration will begin with the transfer of Prolific’s process to Zylidac’s facility at a 50-liter scale, with the goal of reproducing results achieved by Prolific. The companies plan to progress client programs to 250 liters and then to GMP manufacturing. Prolific’s illumination hardware is designed to work with Zylidac’s existing bioreactors, eliminating the need for customers to build new manufacturing infrastructure.
Prolific’s platform uses light to control protein expression in engineered cell lines. It combines optogenetics-enabled cell lines, illumination systems compatible with standard bioreactors, AI-driven process optimization and advanced analytics. The technology is intended for proteins that can be difficult to express, including multispecific antibodies, fusion proteins, cytokines and other complex modalities. Prolific reported productivity of 21 g/L in a 15-day intensified fed-batch Chinese hamster ovary (CHO) run for a monoclonal antibody at small scale, as well as titer increases of up to threefold for other complex formats.
The partnership is intended to provide an integrated development and manufacturing pathway, allowing programs to move from cell line development at Prolific to process scale-up and manufacturing at Zylidac. Zylidac’s capabilities include drug substance and drug product manufacturing, fill-finish and packaging, supporting programs through clinical and commercial supply.
“After demonstrating success at development scale with industry-leading yields across mAbs and difficult-to-express proteins, the next step is scaling the technology to GMP production for clinical and commercial supply.”
Deniz Kent, Ph.D., CEO and co-founder of Prolific Machines
Steve Lavezoli, chief commercial officer of Zylidac, said the companies’ capabilities are complementary, with Prolific focused on early-stage cell line development and Zylidac providing process development, scale-up and GMP manufacturing capacity.







